What top creators are saying about Arrowhead Pharmaceuticals, Inc.(ARWR)

The speaker calls reported durable target reductions of up to 73% in healthy volunteers impressive and views delivery of the drug to the brain as bullish.

The speaker highlighted reductions of up to 73% in healthy volunteers and called the prospect of delivering treatment to the brain impressive and bullish.

Strongly positive clinical and fundamental view following positive clinical trial data and event reduction updates.

Identified as a potential short opportunity.

Mentioned as a partner to Sarepta that accepted stock instead of cash, a move seen as a bullish sign of financial strength for Sarepta.

Mentioned positively as a partner with Sarepta for a new siRNA platform, which helps diversify Sarepta's pipeline into new disease areas.